Aucun résultat
My goal is to improve the health of Canadians and others by generating the real-world evidence needed to balance the safety and effectiveness of prescription drugs. I use large, population-based databases to conduct rigorous pharmacoepidemiologic research on clinically important and policy relevant questions — particularly around drugs used to treat cardiometabolic conditions such as diabetes, heart disease, and hypertension. My work spans two complementary themes: comparative effectiveness and safety. I complement these database studies with knowledge syntheses, applied methodological research, and clinical trials. By providing clinicians, patients, and regulators with the evidence needed for informed decision-making, my program has a direct public health impact in Canada and internationally.
My research program uses population-based databases and cutting-edge pharmacoepidemiologic methods to study medication comparative effectiveness and safety in real-world settings. It is particularly focused on cardiometabolic conditions such as diabetes, heart disease, and hypertension.
I am a Steering Committee member and CPRD Team Lead of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian network that addresses urgent drug safety and effectiveness questions for Health Canada, Canada’s Drug Agency, and provincial/territorial drug plan managers.
I complement my database studies with knowledge syntheses (systematic reviews and meta-analyses) and applied methodological research.
I am the methods lead of the CIHR-funded “Aggressive Smoking Cessation Therapy Among People at Elevated Cardiovascular Risk (ASAP) Trial”, a multi-centre clinical trial that assesses the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk
Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Ann Intern Med. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590. PMID: 39761578.
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB. Diabetes Obes Metab. 2026;28:935-945. doi: 10.1111/dom.70264. PMID: 41208557.
Brillinger J, Filliter C, Salmasi S, Zapata-Bravo E, Platt RW, Yu OHY, Filion KB. Diabetes Obes Metab. 2026; 28:2113-2122. doi: 10.1111/dom.70397. PMID: 41521903.
Filion KB, Zolotarova T, Hébert-Losier A, Windle SB, Reynier P, Greenspoon T, Brandys T, Fülp T, Nguyen T, Elkouri S, Wilderman I, Bertrand O, Bostwick JA, Lacasse Y, Pakhale S, Eisenberg MJ. JACC Adv. 2025;4(6 Pt 2):101833. doi: 10.1016/j.jacadv.2025.101833. PMID: 40579065.
Haber R, Webster-Clark M, Pratt N, Barclay N, Li X, Maro JC, Platt RW, Prieto-Alhambra D, Filion KB. Pharmacoepidemiol Drug Saf. 2025;34:e70177. doi: 10.1002/pds.70177. PMID: 40619597.
